News | July 08, 2008

Cryoablation Just as Effective as Radiofrequency in Treating Atrial Flutter

July 9, 2008 - New research shows catheter cryoablation is comparably effective to radiofrequency catheter ablation for the treatment of atrial flutter (AFL) and may have some safety advantages over the use of radiofrequency.

The findings are detailed in a study published in the July edition of the HeartRhythm Journal, the journal of the Heart Rhythm Society. This is the first large, multi-center study to prove the acute and long-term safety and efficacy of catheter based-cryoablation for the treatment of AFL, reporting six-month follow-up results for 160 patients.

AFL is characterized by a rapid heartbeat and is caused by a single electrical wave that circulates very rapidly in the atrium, about 300 times a minute, leading to a very fast, steady heartbeat. This rapid heartbeat disrupts the pumping of blood to the heart and complications of atrial flutter can potentially lead to a stroke.

Currently, radiofrequency catheter ablation is a very common and effective treatment of AFL, with cure rates around 95 percent. However, radiofrequency catheter ablation can cause serious side effects, such as coagulum formation or endocardial charring which can lead to potential long-term health complications. Catheter-based cryoablation is said to be a viable and safer alternative to radiofrequency catheter ablation, but its efficiency in treating AFL had not been systematically evaluated in a large clinical trial until now.

The study led by Gregory K. Feld, M.D., of the University of California, San Diego (UCSD) School of Medicine, performed catheter-based cryoablation at 12 medical centers in 160 patients with cavotricuspid isthmus-dependent AFL. Patients were evaluated at one, three and six months and underwent weekly and symptomatic event monitoring. The study revealed 90.2 percent of patients remained clinically free of AFL, proving the effectiveness of cryoablation in the treatment of AFL.

“A study of this size, performed at multiple centers, better validates the safety and efficacy of a device for arrhythmia treatment, compared to smaller, single center studies,” Feld said. “The validity of this large multi-center study proves that cryoablation is reliable treatment of atrial flutter, and is further supported by the many safety advantages cryoablation offers over radiofrequency treatment.”

As shown in this study and others, in addition to the newly proven effectiveness of cryoablation in the treatment of AFL, cryoablation also presents a number of safety advantages over radiofrequency, including: less pain, less risk of coagulum formation, less risk of causing heart block and no risk of causing pulmonary vein stenosis which is the narrowing of the vein caused by heating.

For more information:

Related Content

Biotronik Announces U.S. Launch of Edora HF-T QP CRT Pacemaker
Technology | Cardiac Resynchronization Therapy Devices (CRT)| August 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and commercial availability of Edora HF-T QP, an...
The FDA is concerned about cybersecurity of ICDs and cyber security of other medical devices.
Feature | Cybersecurity| August 16, 2017 | Dave Fornell
There is growing concern among patients and regulators that medical devices, especially implantable electrophysiology
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Merge Hemo cath lab hemodynamics monitoring system.

Hemodynamic data shown on screens from the Merge Hemo recording system. It is among the newer generation hemodynamic systems for cath labs that are more user friendly and have technologies to speed workflow.

Feature | Hemodynamic Monitoring Systems| August 03, 2017 | Dave Fornell
The current generation of...
Left Atrial Pressure Monitor from Vectorious Medical Technologies Offers New Hope for Heart Failure Patients

On of the top stories in July was the introduction of a left atrial pressure monitor from Vectorious Medical Technologies to prevent heart failure patient hospitalizations or readmissions. Read the article"Left Atrial Pressure Monitor Offers New Hope for Heart Failure Patients."

Feature | August 01, 2017 | Dave Fornell
Ohio State Researchers Prove Human Heart's 'Battery' Has Multiple Backups
News | EP Lab| July 27, 2017
July 27, 2017 — There is good news when it comes to the heart’s sinoatrial node (SAN), the body’s natural...
Medtronic Announces First Enrollments in STOP AF First Clinical Trial
News | Ablation Systems| July 24, 2017
Medtronic plc recently announced first enrollments in the STOP AF First clinical trial. The trial will evaluate the...
Biotronik Launches DX Technology for U.S. Heart Failure Patients
News | Cardiac Resynchronization Therapy Devices (CRT)| July 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and availability of the Intica DX and Intica...
Overlay Init